DSP Clinical Research Promotes Senior Executive to Vice President of Business Operations

PARSIPPANY, N.J.--(BUSINESS WIRE)-- DSP Clinical Research announced the promotion of Executive Director of West Coast Operations Brenda Reese to Vice President of Business Operations, effective immediately. DSP is a full-service CRO specializing in small to mid-size pharmaceutical and biotechnology company clinical trial management from setup to NDA submission

Ms. Reese, BSN, RN, CCRA, joined DSP in 2007 as Director of Monitoring and transitioned to the Director of West Coast Operations to establish DSP’s West Coast operations. She has an extensive clinical background as well as business development expertise. This enables Ms. Reese to anticipate, understand and solve the challenges sponsors face from both a scientific and business viewpoint.

DSP President Darlene Panzitta said, “Brenda is doing a great job building and executing our business development and marketing strategies. By moving into more of a business operations role, she will continue positioning DSP for strong growth.”

Ms. Reese has been in the pharmaceutical industry for nearly 15 years. She has a wide depth of experience working within large and small pharmaceuticals companies. Ms. Reese holds a B.S. degree in Nursing and is a registered nurse in the state of California.

Brenda Reese commented, ‘I’ve lived the challenges sponsors face in managing clinical trials. My goal is to market DSP’s unique strengths by promoting the message that DSP enables sponsors to conduct clinical trials on time, on budget, and with excellent data quality.”

Ms. Reese is expert in all phases of clinical study management from setup to NDA submission. Her therapeutic areas of experience include cardiovascular, infectious diseases, women's health, diabetes, oncology, skin infections, pneumonia, chronic bronchitis, CNS, arthritis, GI, BPH, ED, muscle spasm, Crohns, Parkinsons, dermatology, pediatric trials and inpatient trials.

About DSP Clinical Research

DSP is a CRO that specializes in small to mid-size pharmaceutical and biotechnology company clinical trial management from setup to NDA submission. DSP has managed and/or monitored more than 50 Phase I - IV clinical trials in various therapeutic areas, with15 NDAs and 3 PMAs. DSP has developed proprietary proven internal SOPs and QA metrics to ensure that quality systems are in place and rigorously followed during every client's clinical study. For more information on DSP, visit www.dspclinical.com, or call 973-265-1060. Follow DSP Clinical Research on Facebook and Twitter.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6324172&lang=en



CONTACT:

Nashawaty Communications
Brenda Nashawaty, 617-688-3253
[email protected]

KEYWORDS:   United States  North America  California  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo
Photo
 Photo
Brenda Reese, DSP Clinical Research Vice President of Business Operations (Photo: Business Wire)

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.